Smart Stocks Watch: Apricus Bio — Erectile Dysfunction, Anti-Fungals

The San Diego-based pharmaceutical company has five approved products internationally, covering erectile dysfunction (Vitaros), side effects of cancer therapy (Totect and Granisol), coronary artery disease (Nitromist) and dry mouth (Aquoral). After a series of successes in strategic partnerships, acquisitions, peer review and clinical data in Q3, the company is garnering some serious attention.

Read more »

Apricus Bio VP: Drug Delivery Space Is Evolving During Personalized Medicine Surge

Apricus Bio VP Edward Cox discusses the future of drug delivery technology in the rapidly expanding world of personalized medicine.

Read more »